{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:53:19Z","timestamp":1793659999318,"version":"4.5.1"},"reference-count":52,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Autologous hematopoietic stem cells transplantation (AHSCT) has been employed as treatment for severe systemic sclerosis (SSc) with high risk of organ failure. In the last 25 years overall survival and treatment-related mortality have improved, in accordance with a better patient selection and mobilization and conditioning protocols. This review analyzes the evidence from the last 5 years for AHSCT-treated SSc patients, considering in particular the outcomes related to interstitial lung disease. There are increasing data supporting the use of AHSCT in selected patients with rapidly progressive SSc. However, some unmet needs remain, such as an accurate patient selection, pre-transplantation analysis to identify subclinical conditions precluding the transplantation, and the alternatives for post-transplant ILD recurrence.<\/jats:p>","DOI":"10.3390\/cells11050843","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T08:17:03Z","timestamp":1646122623000},"page":"843","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7594-8520","authenticated-orcid":false,"given":"Gianluca","family":"Bagnato","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Versace","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"La Rosa","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"De Gaetano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-5467","authenticated-orcid":false,"given":"Egidio","family":"Imbalzano","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Chiappalone","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Ioppolo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Neal","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Kentucky, Lexington, KY 40506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bitto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1134-7080","authenticated-orcid":false,"given":"Natasha","family":"Irrera","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-8239","authenticated-orcid":false,"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8089-7449","authenticated-orcid":false,"given":"Giovanni","family":"Pioggia","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation, National Research Council of Italy, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/keh671","article-title":"Classification of systemic sclerosis. Visions and reality","volume":"44","author":"Wollheim","year":"2005","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/rheumatology\/kex504","article-title":"Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis","volume":"57","author":"Distler","year":"2018","journal-title":"Rheumatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41584-018-0062-0","article-title":"Major lung complications of systemic sclerosis","volume":"14","author":"Denton","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/rheumatology\/kev016","article-title":"Changes in forced vital capacity over time in systemic sclerosis: Application of group-based trajectory modelling","volume":"54","author":"Man","year":"2015","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30010-2","article-title":"The future of treatment in systemic sclerosis: Can we design better trials?","volume":"2","author":"Pope","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"Eular recommendations for the treatment of systemic sclerosis: A report from the eular scleroderma trials and research group (eustar)","volume":"68","author":"Landewe","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of eular recommendations for the treatment of systemic sclerosis","volume":"76","author":"Fransen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (sls ii): A randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (assist): An open-label, randomized phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs. intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial","volume":"311","author":"Farge","year":"2014","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2147\/JBM.S338077","article-title":"Life after autologous hematopoietic stem cell transplantation for systemic sclerosis","volume":"12","author":"Moraes","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102662","DOI":"10.1016\/j.autrev.2020.102662","article-title":"Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives","volume":"19","author":"Ruscitti","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14397595.2017.1416920","article-title":"Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase ii trial and treatment-related fatal cardiomyopathy","volume":"28","author":"Nakamura","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/s41409-018-0162-0","article-title":"Homeostatic proliferation leads to telomere attrition and increased pd-1 expression after autologous hematopoietic sct for systemic sclerosis","volume":"53","author":"Arruda","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","article-title":"Immune rebound associates with a favorable clinical response to autologous hsct in systemic sclerosis patients","volume":"2","author":"Arruda","year":"2018","journal-title":"Blood Adv."},{"key":"ref_19","first-page":"451","article-title":"Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation","volume":"56","author":"Henes","year":"2017","journal-title":"Rheumatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/bmt.2016.77","article-title":"Evolution of serum cytokine profile after hematopoietic stem cell transplantation in systemic sclerosis patients","volume":"51","author":"Michel","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13075-019-1823-0","article-title":"Cd34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: A post hoc analysis of a phase i\/ii clinical trial conducted in Japan","volume":"21","author":"Ayano","year":"2019","journal-title":"Arthritis. Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10067-017-3954-5","article-title":"Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis","volume":"37","author":"Helbig","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2019.230128","article-title":"Autologous stem cell transplantation for progressive systemic sclerosis: A prospective non-interventional study from the European society for blood and marrow transplantation autoimmune disease working party","volume":"106","author":"Henes","year":"2021","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0388-5","article-title":"Long-term immune reconstitution and t cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients","volume":"10","author":"Farge","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.41519","article-title":"Association of autologous hematopoietic stem cell transplantation in systemic sclerosis with marked improvement in health-related quality of life","volume":"73","author":"Maltez","year":"2021","journal-title":"Arthritis. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/annrheumdis-2020-217058","article-title":"Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: Results of a long-term follow-up multicentre study","volume":"79","author":"Boonstra","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Onida","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42358-021-00166-8","article-title":"Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience","volume":"61","author":"Vasconcelos","year":"2021","journal-title":"Adv. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-020-02255-3","article-title":"Low b cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation","volume":"22","author":"Gernert","year":"2020","journal-title":"Arthritis. Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bmt.1704656","article-title":"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis","volume":"34","author":"Saccardi","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/ard.60.6.577","article-title":"Phase i\/ii trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease","volume":"60","author":"Binks","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V100.5.1602.h81702001602_1602_1610","article-title":"High-dose immunosuppressive therapy for severe systemic sclerosis: Initial outcomes","volume":"100","author":"McSweeney","year":"2002","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","article-title":"High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: Long-term follow-up of the us multicenter pilot study","volume":"110","author":"Nash","year":"2007","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/eurjhf\/hfn012","article-title":"Cyclophosphamide-evoked heart failure involves pronounced co-suppression of cytoplasmic thioredoxin reductase activity and non-protein free thiol level","volume":"11","author":"Wang","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00296-016-3531-2","article-title":"Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation","volume":"36","author":"Massenkeil","year":"2016","journal-title":"Rheumatol. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1183\/09031936.00091212","article-title":"High prevalence of occult left heart disease in scleroderma-pulmonary hypertension","volume":"42","author":"Fox","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2017.56","article-title":"Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: Recommendations from the European society for blood and marrow transplantation autoimmune diseases working party and collaborating partners","volume":"52","author":"Farge","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/BOR.0000000000000541","article-title":"Hematopoietic stem-cell transplantation in systemic sclerosis: An update","volume":"30","author":"Spierings","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/rheumatology\/kez300","article-title":"Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant-a systematic review","volume":"59","author":"Puyade","year":"2020","journal-title":"Rheumatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1759720X211035196","DOI":"10.1177\/1759720X211035196","article-title":"Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: Early action in selected patients rather than escalation therapy for all","volume":"13","author":"Spierings","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/acr.24451","article-title":"Evolution of systemic sclerosis-associated interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide","volume":"74","author":"Ciaffi","year":"2022","journal-title":"Arthritis. Care Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: A subgroup analysis of the senscis trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3389\/fimmu.2018.02390","article-title":"Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis","volume":"9","author":"Pignataro","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"817893","DOI":"10.3389\/fimmu.2021.817893","article-title":"Immunosuppressive therapy after autologous hematopoietic stem cell transplantation in systemic sclerosis patients-high efficacy of rituximab","volume":"12","author":"Gernert","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/keq414","article-title":"Analysis of immune reconstitution after autologous cd34+ stem\/progenitor cell transplantation for systemic sclerosis: Predominant reconstitution of th1 cd4+ t cells","volume":"50","author":"Tsukamoto","year":"2011","journal-title":"Rheumatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1093\/rheumatology\/keab257","article-title":"Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory b cells in systemic sclerosis patients","volume":"60","author":"Arruda","year":"2021","journal-title":"Rheumatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"723349","DOI":"10.3389\/fimmu.2021.723349","article-title":"Immunological adverse events after autologous hematopoietic stem cell transplantation in systemic sclerosis patients","volume":"12","author":"Strunz","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41409-020-0978-2","article-title":"Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: A pilot safety study that decreases neutropenic interval to 5 days","volume":"56","author":"Burt","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.retram.2016.03.003","article-title":"Haematopoietic stem cell transplantation in autoimmune diseases: From basic science to clinical practice","volume":"64","author":"Kelsey","year":"2016","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3899\/jrheum.181173","article-title":"Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis","volume":"47","author":"Allanore","year":"2020","journal-title":"J. Rheumatol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/5\/843\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:30:06Z","timestamp":1760135406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/5\/843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cells11050843"],"URL":"https:\/\/doi.org\/10.3390\/cells11050843","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}